{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:25:55Z","timestamp":1761870355808,"version":"build-2065373602"},"reference-count":43,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2011,8,1]],"date-time":"2011-08-01T00:00:00Z","timestamp":1312156800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,8,1]],"date-time":"2011-08-01T00:00:00Z","timestamp":1312156800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2011,8]]},"DOI":"10.1016\/j.clml.2011.06.004","type":"journal-article","created":{"date-parts":[[2011,8,3]],"date-time":"2011-08-03T17:27:53Z","timestamp":1312392473000},"page":"355-360","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Pilot Study of Bortezomib for Patients With Imatinib-Refractory Chronic Myeloid Leukemia in Chronic or Accelerated Phase"],"prefix":"10.1016","volume":"11","author":[{"given":"Fabio P.S.","family":"Santos","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hagop","family":"Kantarjian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"McConkey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan","family":"O'Brien","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Faderl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gautam","family":"Borthakur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandra","family":"Ferrajoli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Wright","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorge","family":"Cortes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2011.06.004_bib1","doi-asserted-by":"crossref","first-page":"6041","DOI":"10.1200\/JCO.2009.25.0779","article-title":"Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet","volume":"27","author":"Baccarani","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2011.06.004_bib2","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V114.22.1126.1126","article-title":"International Randomized Study of Interferon Vs STI571 (IRIS) 8-year follow up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib","volume":"114","author":"Deininger","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.06.004_bib3","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1016\/S1470-2045(07)70342-X","article-title":"Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia","volume":"8","author":"Apperley","year":"2007","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2011.06.004_bib4","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1038\/leu.2008.84","article-title":"Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib","volume":"22","author":"Hochhaus","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2011.06.004_bib5","doi-asserted-by":"crossref","first-page":"3540","DOI":"10.1182\/blood-2007-03-080689","article-title":"Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance","volume":"110","author":"Kantarjian","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.06.004_bib6","doi-asserted-by":"crossref","first-page":"3472","DOI":"10.1200\/JCO.2007.14.3339","article-title":"Dasatinib in the treatment of chronic myeloid leukemia in accelerated phase after imatinib failure: the START a trial","volume":"27","author":"Apperley","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2011.06.004_bib7","doi-asserted-by":"crossref","first-page":"2176","DOI":"10.1038\/leu.2008.221","article-title":"Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase","volume":"22","author":"Cortes","year":"2008","journal-title":"Leukemia"},{"issue":"suppl","key":"10.1016\/j.clml.2011.06.004_bib8","article-title":"Nilotinib in patients (pts) with Philadelphia chromosome-positive (ph+) chronic myelogenous leukemia in blast crisis (CML-BC) who are resistant or intolerant to imatinib","volume":"26","author":"Giles","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2011.06.004_bib9","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1182\/blood-2007-04-083196","article-title":"Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia","volume":"111","author":"le Coutre","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.06.004_bib10","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1172\/JCI30890","article-title":"Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency","volume":"117","author":"Shah","year":"2007","journal-title":"J Clin Invest"},{"key":"10.1016\/j.clml.2011.06.004_bib11","doi-asserted-by":"crossref","first-page":"4532","DOI":"10.1182\/blood-2005-07-2947","article-title":"Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction","volume":"107","author":"Copland","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.06.004_bib12","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1182\/blood.V99.1.319","article-title":"Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro","volume":"99","author":"Graham","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.06.004_bib13","doi-asserted-by":"crossref","first-page":"4016","DOI":"10.1182\/blood-2006-11-057521","article-title":"Nilotinib exerts equipotent antiproliferative effects to imatinib and does not induce apoptosis in CD34+ CML cells","volume":"109","author":"Jorgensen","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.06.004_bib14","doi-asserted-by":"crossref","first-page":"4701","DOI":"10.1182\/blood-2002-09-2780","article-title":"Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment","volume":"101","author":"Bhatia","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.06.004_bib15","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1182\/blood-2006-03-011239","article-title":"Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years","volume":"109","author":"Rousselot","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.06.004_bib16","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1038\/sj.onc.1202189","article-title":"Interaction with cyclin-dependent kinases and PCNA modulates proteasome-dependent degradation of p21","volume":"17","author":"Cayrol","year":"1998","journal-title":"Oncogene"},{"key":"10.1016\/j.clml.2011.06.004_bib17","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1006\/bbrc.1999.1291","article-title":"Phosphorylation and proteasome-dependent degradation of Bcl-2 in mitotic-arrested cells after microtubule damage","volume":"262","author":"Chadebech","year":"1999","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.clml.2011.06.004_bib18","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1101\/gad.10.16.1979","article-title":"Turnover of cyclin E by the ubiquitin-proteasome pathway is regulated by cdk2 binding and cyclin phosphorylation","volume":"10","author":"Clurman","year":"1996","journal-title":"Genes Dev"},{"key":"10.1016\/j.clml.2011.06.004_bib19","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1126\/science.7624798","article-title":"Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27","volume":"269","author":"Pagano","year":"1995","journal-title":"Science"},{"key":"10.1016\/j.clml.2011.06.004_bib20","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/S0092-8674(94)90482-0","article-title":"The ubiquitin-proteasome pathway is required for processing the NF-kappa B1 precursor protein and the activation of NF-kappa B","volume":"78","author":"Palombella","year":"1994","journal-title":"Cell"},{"key":"10.1016\/j.clml.2011.06.004_bib21","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/b136681","article-title":"The ubiquitin-proteasome pathway in cell cycle control","volume":"42","author":"Reed","year":"2006","journal-title":"Results Probl Cell Differ"},{"key":"10.1016\/j.clml.2011.06.004_bib22","first-page":"1428","article-title":"Proteasome proteolytic activity in hematopoietic cells from patients with chronic myeloid leukemia and multiple myeloma","volume":"89","author":"Magill","year":"2004","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2011.06.004_bib23","doi-asserted-by":"crossref","first-page":"3264","DOI":"10.1158\/0008-5472.CAN-04-1357","article-title":"BCR-ABL induces the expression of Skp2 through the PI3K pathway to promote p27Kip1 degradation and proliferation of chronic myelogenous leukemia cells","volume":"65","author":"Andreu","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.clml.2011.06.004_bib24","doi-asserted-by":"crossref","first-page":"39223","DOI":"10.1074\/jbc.M007291200","article-title":"BCR\/ABL regulates expression of the cyclin-dependent kinase inhibitor p27Kip1 through the phosphatidylinositol 3-kinase\/AKT pathway","volume":"275","author":"Gesbert","year":"2000","journal-title":"J Biol Chem"},{"key":"10.1016\/j.clml.2011.06.004_bib25","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1182\/blood.V96.5.1933","article-title":"Bcr-Abl kinase down-regulates cyclin-dependent kinase inhibitor p27 in human and murine cell lines","volume":"96","author":"Jonuleit","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.06.004_bib26","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1101\/gad.12.10.1415","article-title":"Oncogenic Abl and Src tyrosine kinases elicit the ubiquitin-dependent degradation of target proteins through a Ras-independent pathway","volume":"12","author":"Dai","year":"1998","journal-title":"Genes Dev"},{"key":"10.1016\/j.clml.2011.06.004_bib27","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1038\/sj.onc.1201411","article-title":"Activation of p65 NF-kappaB protein by p210BCR-ABL in a myeloid cell line (P210BCR-ABL activates p65 NF-kappaB)","volume":"15","author":"Hamdane","year":"1997","journal-title":"Oncogene"},{"key":"10.1016\/j.clml.2011.06.004_bib28","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1101\/gad.12.7.968","article-title":"A requirement for NF-kappaB activation in Bcr-Abl-mediated transformation","volume":"12","author":"Reuther","year":"1998","journal-title":"Genes Dev"},{"key":"10.1016\/j.clml.2011.06.004_bib29","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/S0022-3565(24)38201-1","article-title":"Proteasome inhibition leads to significant reduction of Bcr-Abl expression and subsequent induction of apoptosis in K562 human chronic myelogenous leukemia cells","volume":"289","author":"Dou","year":"1999","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.clml.2011.06.004_bib30","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1056\/NEJMoa030288","article-title":"A phase 2 study of bortezomib in relapsed, refractory myeloma","volume":"348","author":"Richardson","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2011.06.004_bib31","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1056\/NEJMoa043445","article-title":"Bortezomib or high-dose dexamethasone for relapsed multiple myeloma","volume":"352","author":"Richardson","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2011.06.004_bib32","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1056\/NEJMoa0801479","article-title":"Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma","volume":"359","author":"San Miguel","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2011.06.004_bib33","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.1182\/blood-2008-06-164582","article-title":"Bortezomib induces apoptosis in primitive chronic myeloid leukemia cells including LTC-IC and NOD\/SCID repopulating cells","volume":"115","author":"Heaney","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.06.004_bib34","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1002\/(SICI)1097-0258(19980730)17:14<1563::AID-SIM873>3.0.CO;2-L","article-title":"Some extensions and applications of a Bayesian strategy for monitoring multiple outcomes in clinical trials","volume":"17","author":"Thall","year":"1998","journal-title":"Stat Med"},{"key":"10.1016\/j.clml.2011.06.004_bib35","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric estimation from incomplete observations","volume":"53","author":"Kaplan","year":"1958","journal-title":"J Am Stat Assoc"},{"key":"10.1016\/j.clml.2011.06.004_bib36","article-title":"Predictive Factors for Response and Outcome in patients (pts) treated with second generation tyrosine kinase inhibitors (2-TKI) for chronic myeloid leukemia in chronic phase (CML-CP) post imatinib failure","volume":"114","author":"Jabbour","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.06.004_bib37","doi-asserted-by":"crossref","first-page":"4745","DOI":"10.1182\/blood-2010-07-294983","article-title":"Efficacy and safety of once weekly bortezomib in multiple myeloma patients","volume":"116","author":"Bringhen","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.06.004_bib38","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1182\/blood-2008-04-149385","article-title":"Bortezomib-induced peripheral neuropathy in multiple myeloma: a comprehensive review of the literature","volume":"112","author":"Argyriou","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.06.004_bib39","doi-asserted-by":"crossref","first-page":"3113","DOI":"10.1200\/JCO.2005.04.7779","article-title":"Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib","volume":"24","author":"Richardson","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2011.06.004_bib40","first-page":"853","article-title":"The proteasome inhibitor PS-341 inhibits growth and induces apoptosis in Bcr\/Abl-positive cell lines sensitive and resistant to imatinib mesylate","volume":"88","author":"Gatto","year":"2003","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2011.06.004_bib41","doi-asserted-by":"crossref","first-page":"3276","DOI":"10.1038\/onc.2010.81","article-title":"Bortezomib decreases Rb phosphorylation and induces caspase-dependent apoptosis in imatinib-sensitive and -resistant Bcr-Abl1-expressing cells","volume":"29","author":"Albero","year":"2010","journal-title":"Oncogene"},{"key":"10.1016\/j.clml.2011.06.004_bib42","doi-asserted-by":"crossref","first-page":"3281","DOI":"10.1182\/blood-2007-01-065888","article-title":"Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma","volume":"110","author":"Kuhn","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.06.004_bib43","article-title":"Initial results of PX-171-003, an open-label, single-arm, phase II study of carfilzomib (CFZ) in patients with relapsed and refractory multiple myeloma (MM)","volume":"116","author":"Jagannath","year":"2010","journal-title":"Blood"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265011001996?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265011001996?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:22:14Z","timestamp":1761870134000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265011001996"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,8]]},"references-count":43,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2011,8]]}},"alternative-id":["S2152265011001996"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2011.06.004","relation":{},"ISSN":["2152-2650"],"issn-type":[{"type":"print","value":"2152-2650"}],"subject":[],"published":{"date-parts":[[2011,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pilot Study of Bortezomib for Patients With Imatinib-Refractory Chronic Myeloid Leukemia in Chronic or Accelerated Phase","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2011.06.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}